Lisa Tuomi

HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Michael Singer, Carl C. Awh, Srinivas R. Sadda et al. · Ophthalmology · 2012 · 355 citations

Ocular Disease, Open-label Extension Trial, Ophthalmology +5

Characteristics of Patients Losing Vision after 2 Years of Monthly Dosing in the Phase III Ranibizumab Clinical Trials

Philip J. Rosenfeld, Howard Shapiro, Lisa Tuomi et al. · Ophthalmology · 2010 · 251 citations

Ocular Disease, Ophthalmology, Visual Impairment +4

Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach

Lu Xu, Tong Lu, Lisa Tuomi et al. · Investigative Ophthalmology & Visual Science · 2013 · 196 citations

Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results

Andrew N. Antoszyk, Lisa Tuomi, Carol Chung et al. · American Journal of Ophthalmology · 2008 · 191 citations

Verteporfin Photodynamic Therapy, Ocular Disease, Ophthalmology +7

Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration

Srinivas R. Sadda, Lisa Tuomi, Beiying Ding et al. · Ophthalmology · 2018 · 131 citations